2-(4-iodo-1H-pyrazol-3-yl)-6-methylpyridine | 1184917-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(4-iodo-1H-pyrazol-3-yl)-6-methylpyridine
• 英文别名: 2-(4-iodo-1H-pyrazol-5-yl)-6-methylpyridine
• CAS: 1184917-36-9
• 化学式: C₉H₈IN₃
• 分子量: 285.087
• InChiKey: SRQZMQGQTNZXQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-iodo-1H-pyrazol-3-yl)-6-methylpyridine 在 盐酸 、 XPhos Pd G2 、 potassium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 8.0h， 生成 5-(((trans-3-(4-cyclopropyl-3-(6-methylpyridin-2-yl)-1H-pyrazol-1-yl)cyclobutyl)methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF TREATING CANCERS
  [FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS

  摘要：

  This disclosure relates to GSPT1 degrader compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds or salts, and methods of making and using the compounds or salts for the treatment of certain diseases. The disclosure also relates to methods for identifying such compounds.

  公开号：

  WO2023193760A1
• 作为产物：
  描述：

  2-甲基-6-(1H-吡唑-3-基)吡啶 在 N-碘代丁二酰亚胺 、 三氟乙酸 作用下， 以59 %的产率得到2-(4-iodo-1H-pyrazol-3-yl)-6-methylpyridine
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF TREATING CANCERS
  [FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS

  摘要：

  This disclosure relates to GSPT1 degrader compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds or salts, and methods of making and using the compounds or salts for the treatment of certain diseases. The disclosure also relates to methods for identifying such compounds.

  公开号：

  WO2023193760A1

文献信息

• [EN] TGF Beta RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR TGF-β
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018017633A1

  公开（公告）日：2018-01-25

  The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  这项发明通常涉及调节TGFβR-1和TGFβR-2活性的化合物，包含这些化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病（如癌症）的方法。
• TGF Beta RECEPTOR ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190292179A1

  公开（公告）日：2019-09-26

  The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
• [EN] COMPOUNDS AND METHODS OF TREATING CANCERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS
  申请人：[en]CULLGEN (SHANGHAI) , INC.

  公开号：WO2023193760A1

  公开（公告）日：2023-10-12

  This disclosure relates to GSPT1 degrader compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds or salts, and methods of making and using the compounds or salts for the treatment of certain diseases. The disclosure also relates to methods for identifying such compounds.